7,058 Shares in Medpace Holdings, Inc. $MEDP Acquired by Militia Capital Management LLC

Militia Capital Management LLC acquired a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP) during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 7,058 shares of the company’s stock, valued at approximately $3,389,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of MEDP. AQR Capital Management LLC raised its position in shares of Medpace by 65.1% during the 3rd quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock valued at $518,170,000 after acquiring an additional 404,226 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its position in shares of Medpace by 205.8% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock worth $161,523,000 after purchasing an additional 211,411 shares during the last quarter. Franklin Resources Inc. boosted its position in shares of Medpace by 158.6% in the 4th quarter. Franklin Resources Inc. now owns 299,472 shares of the company’s stock worth $168,198,000 after purchasing an additional 183,645 shares during the last quarter. Norges Bank acquired a new stake in shares of Medpace during the fourth quarter worth $102,156,000. Finally, Goldman Sachs Group Inc. grew its stake in shares of Medpace by 92.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 347,049 shares of the company’s stock worth $194,920,000 after purchasing an additional 166,654 shares during the period. 77.98% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

MEDP has been the topic of several analyst reports. Leerink Partners set a $620.00 target price on Medpace in a research note on Thursday, July 23rd. BMO Capital Markets boosted their target price on Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a research report on Friday, July 24th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Medpace in a research note on Thursday, July 2nd. Mizuho increased their price target on shares of Medpace from $586.00 to $665.00 and gave the company an “outperform” rating in a research report on Friday, July 24th. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a $535.00 price objective on shares of Medpace in a research note on Thursday, July 23rd. Two investment analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $584.18.

Insider Activity at Medpace

In related news, VP Susan E. Burwig sold 7,500 shares of the stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $600.00, for a total transaction of $4,500,000.00. Following the completion of the sale, the vice president directly owned 62,984 shares of the company’s stock, valued at approximately $37,790,400. This represents a 10.64% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO August J. Troendle sold 3,728 shares of the firm’s stock in a transaction that occurred on Monday, July 27th. The stock was sold at an average price of $600.85, for a total transaction of $2,239,968.80. Following the sale, the chief executive officer owned 642,456 shares in the company, valued at $386,019,687.60. This trade represents a 0.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 31,087 shares of company stock worth $16,203,054. 20.50% of the stock is owned by company insiders.

Medpace Stock Performance

Shares of Medpace stock opened at $577.11 on Monday. The company has a market capitalization of $16.11 billion, a PE ratio of 33.83, a PEG ratio of 2.57 and a beta of 1.15. Medpace Holdings, Inc. has a 12 month low of $373.00 and a 12 month high of $677.90. The stock’s fifty day simple moving average is $507.61 and its 200 day simple moving average is $493.03.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.98 by $0.27. The company had revenue of $707.33 million during the quarter, compared to the consensus estimate of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The company’s revenue for the quarter was up 17.2% compared to the same quarter last year. During the same period in the prior year, the company earned $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Analysts predict that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.